Acute intoxications require rapid and targeted treatment to reduce the amount of toxic substances in the body. The HA230 hemoadsorption cartridge provides an additional treatment option by extracorporeally adsorbing drugs, pesticides and other toxic substances from the blood.
The cartridge can be used as a stand-alone hemoperfusion treatment or as part of an extracorporeal circuit in combination with haemodialysis, haemofiltration, haemodiafiltration or continuous renal replacement therapy, among others.
Not all toxic substances can be removed equally effectively using conventional dialysis techniques. High protein binding and lipophilicity, in particular, may limit their removal by dialysis. Hemoadsorption provides an additional mechanism of action in which molecules bind to the adsorbent material inside the cartridge.
The HA230 contains a porous adsorbent resin made of double cross-linked styrene-divinylbenzene copolymer with a biocompatible collodion coating. Its large available adsorption surface supports the binding of various endogenous and exogenous molecules. Blood is passed through the cartridge, where the bound substances are retained by the adsorbent material, after which the blood is returned to the patient.
The cartridge is indicated for the removal of overdosed drugs and toxic substances, including carbamazepine, organophosphates and paraquat. However, the available clinical evidence varies by substance and type of intoxication.
The potential value of early hemoperfusion has been investigated in patients with carbamazepine intoxication. Carbamazepine is highly protein-bound, which may limit its removal using conventional dialysis techniques.
In a retrospective study involving 104 patients, early hemoperfusion using the HA230 was compared with hemoperfusion initiated later and treatment without hemoperfusion. Early treatment was associated with a shorter carbamazepine retention time, more favourable pharmacokinetic parameters and a shorter hospital stay. Differences were also observed in levels of consciousness, respiratory depression and the occurrence of seizures.¹
The results support a potential role for timely extracorporeal adsorption as an adjunctive treatment in selected cases of severe carbamazepine intoxication.
The HA230 has also been investigated in critically ill patients with suspected organophosphate or carbamate poisoning. In a prospective randomised study, treatment with the HA230 in combination with standard care was compared with standard care alone.
No statistically significant difference was demonstrated for overall ICU length of stay, the study’s primary outcome. In a post hoc analysis of patients who remained in intensive care for at least seven days, hemoadsorption was associated with a shorter median ICU stay, a shorter duration of mechanical ventilation and a shorter duration of antidote therapy. The combined outcome of 28-day mortality and severe complications also occurred less frequently in the hemoadsorption group. There was no statistically significant difference between the groups in 28-day mortality when assessed separately.²
These results indicate that hemoadsorption may play an adjunctive role in the treatment of selected severe pesticide intoxications.
Depending on the clinical situation, the HA230 can be used as a stand-alone hemoperfusion treatment or in combination with:
This allows the cartridge to be incorporated into different extracorporeal treatment configurations. The choice of configuration depends on factors including the toxic substance involved, the severity and timing of the intoxication, the patient’s condition and the availability of standard treatment or antidote therapy.
Tubing sets and collection bags
As an addition to our product range, we can also supply the corresponding tubing sets and collection bags.
1 Yang, X., Xin, S., Zhang, Y., & Li, T. (2018). Early hemoperfusion for emergency treatment of carbamazepine poisoning. The American Journal of Emergency Medicine, 36(6), 926–930. https://doi.org/10.1016/j.ajem.2017.10.048
2 Omar, S., Sooka, P. N., Khoza, S., Van Rooyen, M. C., Mashamba, L., Madi, S., Mathivha, L. R., & George, J. A. (2023). Hemoperfusion for clinically suspected organophosphate and carbamate poisoning in critically ill patients: A randomized trial. Blood Purification, 52(2), 157–165. https://doi.org/10.1159/000525936
Would you like to receive more information about this product, or request a quote? Klik hier!
| Color | Multiple |
| Product code | HM-675113 |
| Unit of Measure | See product table |
| Classification | Medical Device class IIb |
| Certification |
|
| Material | Multiple |
| Applications | The Jafron HA230 is intended for the extracorporeal removal of overdosed drugs and toxic substances, including carbamazepine, organophosphates and paraquat. The cartridge can be used as a stand-alone haemoperfusion treatment or in combination with HD, HF or HDF. |
Order code |
Key Features |
Adsorbent Volume |
Packing Unit |
| HM-675113 | The HA230 is a hemoadsorption cartridge for the extracorporeal removal of overdosed drugs and toxic substances, including carbamazepine, organophosphates and paraquat | 230 ml | BOX/20 |
